Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC

Clinical trial NCT07639242 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07639242
Sponsor: UNC Lineberger Comprehensive Cancer Center
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer Lung Cancer (NSCLC)Locally Advanced NSCLC Metastatic NSCLC - Non-Small Cell Lung Cancer

Start date: 2026-06-01
Primary completion: 2030-06-21
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.